Statin use and kidney cancer outcomes: A propensity score analysis

Urologic Oncology: Seminars and Original Investigations

Volumn 34, Issue 11, 2016, Pages 487.e1-487.e6

  Nayan, Madhur ^a   Finelli, Antonio ^a   Jewett, Michael A S ^a   Juurlink, David N ^b   Austin, Peter C ^c,d,e   Kulkarni, Girish S ^a   Hamilton, Robert J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Canada   (Canada)

Author keywords

HMG CoA reductase inhibitor; Kidney neoplasms; Nephrectomy; Propensity score; Survival

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CHARLSON COMORBIDITY INDEX; CLINICAL OUTCOME; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; KAPLAN MEIER METHOD; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RENAL CELL CARCINOMA; TREATMENT OUTCOME;

AGED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84978897547     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2016.06.007     Document Type: Article

References (32)

1. [1] Cancer IAfRo, Organization WH. GLOBOCAN: Estimated cancer incidence, mortality, and prevalence worldwide in 2012. IARC; 2014.
2. [2] Chow, W.H., Dong, L.M., Devesa, S.S., Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7 (2010), 245–257, 10.1038/nrurol.2010.46.
3. [3] Gazzerro, P., Proto, M.C., Gangemi, G., Malfitano, A.M., Ciaglia, E., Pisanti, S., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 64 (2012), 102–146.
4. [4] Law, M., Rudnicka, A.R., Statin safety: a systematic review. Am J Cardiol 97 (2006), S52–S60.
5. [5] Nielsen, S.F., Nordestgaard, B.G., Bojesen, S.E., Statin use and reduced cancer-related mortality. N Engl J Med 367 (2012), 1792–1802.
6. [6] Manoukian, G.E., Tannir, N.M., Jonasch, E., Qiao, W., Haygood, T.M., Tu, S.-M., Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 9 (2011), 81–88.
7. [7] Han, J.-Y., Lee, S.-H., Yoo, N.J., Hyung, L.S., Moon, Y.J., Yun, T., et al. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non–small cell lung cancer. Clin Cancer Res 17 (2011), 1553–1560.
8. [8] Demierre, M.-F., Higgins, P.D., Gruber, S.B., Hawk, E., Lippman, S.M., Statins and cancer prevention. Nat Rev Cancer 5 (2005), 930–942.
9. [9] Hamilton, R.J., Morilla, D., Cabrera, F., Leapman, M., Chen, L.Y., Bernstein, M., et al. The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol 191 (2014), 914–919.
10. [10] Kaffenberger, S.D., Lin-Tsai, O., Stratton, K.L., Morgan, T.M., Barocas, D.A., Chang, S.S., et al. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol, 1, 2015 [21.e11–21. e17].
11. [11] Krane, L.S., Sandberg, J.M., Rague, J.T., Hemal, A.K., Do statin medications impact renal functional or oncologic outcomes for robot-assisted partial nephrectomy?. J Endourol 28 (2014), 1308–1312.
12. [12] Viers, B.R., Thompson, R.H., Psutka, S.P., Lohse, C.M., Cheville, J.C., Leibovich, B.C., et al. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urol Oncol, 33, 2015 [388-e11].
13. [13] Choi, S.-K., Min, G.E., Jeon, S.H., Lee, H.-L., Chang, S.-G., Yoo, K.H., Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. Mol Clin Oncol 1 (2013), 365–368.
14. [14] Clarke, E., Marrett, L., Kreiger, N., In: Jenson OM, Parkin DM, MacLennan R (eds.). Appendix 3 (c) Cancer registration in Ontario: a computer approach. Cancer Registration: Principles and Methods, vol. 95, 1991, Lyon, France: IARC Publication, 246–257.
15. [15] Brenner, D.R., Tammemagi, M.C., Bull, S.B., Pinnaduwaje, D., Andrulis, I.L., Using cancer registry data: agreement in cause-of-death data between the Ontario Cancer Registry and a longitudinal study of breast cancer patients. Chronic Dis Can 30 (2009), 16–19.
16. [16] Austin, P.C., Stuart, E.A., Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34 (2015), 3661–3679.
17. [17] Brookhart, M.A., Wyss, R., Layton, J.B., Stürmer, T., Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 6 (2013), 604–611.
18. [18] Austin, P.C., The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33 (2014), 1242–1258.
19. [19] Austin, P.C., Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10 (2011), 150–161.
20. [20] Austin, P.C., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46 (2011), 399–424.
21. [21] Austin, P.C., Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf 17 (2008), 1218–1225.
22. [22] Austin, P.C., Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28 (2009), 3083–3107.
23. [23] Cole, S.R., Hernán, M.A., Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 75 (2004), 45–49.
24. [24] Lin, D.Y., Wei, L.-J., Ying, Z., Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 80 (1993), 557–572.
25. [25] Aron, M., Nguyen, M.M., Stein, R.J., Gill, I.S., Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 54 (2008), 133–142.
26. [26] Ather, M.H., Nazim, S.M., Impact of Charlson׳s comorbidity index on overall survival following tumor nephrectomy for renal cell carcinoma. Int Urol Nephrol 42 (2010), 299–303.
27. [27] Gettman, M.T., Boelter, C.W., Cheville, J.C., Zincke, H., Bryant, S.C., Blute, M.L., Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol 169 (2003), 1282–1286.
28. [28] Arrontes, D.S., Aceñero, M.J.F., González, J.I.G., Muñoz, M.M., Andrés, P.P., Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 179 (2008), 857–861.
29. [29] Margel, D., Urbach, D.R., Lipscombe, L.L., Bell, C.M., Kulkarni, G., Austin, P.C., et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31 (2013), 3069–3075, 10.1200/JCO.2012.46.7043.
30. [30] Lega, I.C., Austin, P.C., Gruneir, A., Goodwin, P.J., Rochon, P.A., Lipscombe, L.L., Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 36 (2013), 3018–3026, 10.2337/dc12-2535.
31. [31] Austin, P.C., Mamdani, M.M., A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 25 (2006), 2084–2106.
32. [32] McKay, R.R., Lin, X., Albiges, L., Fay, A.P., Kaymakcalan, M.D., Mickey, S.S., et al. Statins and survival outcomes in patients with metastatic renal cell carcinoma. Eur J Cancer 52 (2016), 155–162.